Not sure what to think about TRMS. Initial Fuzeon sales were below expectations, and it looks like the stock's price over the past 5 years reflect pure hype around the drug. The only other drug in the pipeline for this small 129 employee biotech firm is a second version of Fuzeon that binds to a different area of the receptor. This drug is currently in Phase II and apparently there is not much else to help the stock recover.It's interesting that institutions jumped on this as well following the drop. Is this a result of some "stock-picking" computers at work or is there potential upside that I'm missing?Incidentally, there's new news on 48-week data released today:http://www.trimeris.com/news/pr/2003/031216.htmlAlso, being a web developer, I have to commend them on their Fuzeon site - http://www.fuzeon.com - although I prefer PHP, the layout is well done.Cheers,GoofyFool
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. M